OTCM
ABMC
Market cap0kUSD
Feb 25, Last price
0.00USD
Name
American Bio Medica Corp
Chart & Performance
Profile
American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides strip contract manufacturing, assembly, and packaging services to non-affiliated diagnostic companies. The company serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets. It operates in the United States, Europe, the Asia Pacific, and South America. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||
Revenues | 913 -58.84% | |||||||
Cost of revenue | 2,245 | |||||||
Unusual Expense (Income) | ||||||||
NOPBT | (1,332) | |||||||
NOPBT Margin | ||||||||
Operating Taxes | 2 | |||||||
Tax Rate | ||||||||
NOPAT | (1,334) | |||||||
Net income | (1,410) 204.54% | |||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
Debt | ||||||||
Debt current | 2,234 | |||||||
Long-term debt | 16 | |||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 2,216 | |||||||
Cash flow | ||||||||
Cash from operating activities | (768) | |||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | 687 | |||||||
FCF | (692) | |||||||
Balance | ||||||||
Cash | 34 | |||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | (24,742) | |||||||
Invested Capital | 24,455 | |||||||
ROIC | ||||||||
ROCE | 464.11% | |||||||
EV | ||||||||
Common stock shares outstanding | 48,018 | |||||||
Price | 0.01 -85.33% | |||||||
Market cap | 264 -83.53% | |||||||
EV | 2,480 | |||||||
EBITDA | (1,281) | |||||||
EV/EBITDA | ||||||||
Interest | 194 | |||||||
Interest/NOPBT |